197 related articles for article (PubMed ID: 31718855)
21. Assessment and non-clinical impact of medical devices.
Dervaux B; Szwarcensztein K; Josseran A; ; Barna A; Carbonneil C; Chevrie K; Debroucker F; Grumblat A; Grumel O; Massol J; Maugendre P; Méchin H; Orlikowski D; Roussel C; Rumeau-Pichon C; Sales JP; Vicaut E
Therapie; 2015; 70(1):57-68. PubMed ID: 25747839
[TBL] [Abstract][Full Text] [Related]
22. Direct access and patient/client self-referral to physiotherapy: a review of contemporary practice within the European Union.
Bury TJ; Stokes EK
Physiotherapy; 2013 Dec; 99(4):285-91. PubMed ID: 23537881
[TBL] [Abstract][Full Text] [Related]
23. EU and member state medical devices regulation.
Altenstetter C
Int J Technol Assess Health Care; 2003; 19(1):228-48. PubMed ID: 12701954
[TBL] [Abstract][Full Text] [Related]
24. From medical invention to clinical practice: the reimbursement challenge facing new device procedures and technology--part 2: coverage.
Raab GG; Parr DH
J Am Coll Radiol; 2006 Oct; 3(10):772-7. PubMed ID: 17412167
[TBL] [Abstract][Full Text] [Related]
25. The need for transparency of clinical evidence for medical devices in Europe.
Fraser AG; Butchart EG; Szymański P; Caiani EG; Crosby S; Kearney P; Van de Werf F
Lancet; 2018 Aug; 392(10146):521-530. PubMed ID: 30017550
[TBL] [Abstract][Full Text] [Related]
26. FACTORS INFLUENCING REIMBURSEMENT OF MEDICAL DEVICES IN FRANCE.
Loge P; Delalande F; Reymond MC; Germain S
Int J Technol Assess Health Care; 2015; 31(6):399-406. PubMed ID: 26868190
[TBL] [Abstract][Full Text] [Related]
27. Special funding schemes for innovative medical devices in French hospitals: the pros and cons of two different approaches.
Martelli N; van den Brink H
Health Policy; 2014 Jul; 117(1):1-5. PubMed ID: 24794738
[TBL] [Abstract][Full Text] [Related]
28. Doctors demand to see evidence on safety of medical devices approved in Europe.
Bowers S
BMJ; 2018 Nov; 363():k5105. PubMed ID: 30504128
[No Abstract] [Full Text] [Related]
29. Factors influencing coverage decisions on medical devices: A retrospective analysis of 78 medical device appraisals for the Austrian hospital benefit catalogue 2008-2015.
Kisser A; Tüchler H; Erdös J; Wild C
Health Policy; 2016 Aug; 120(8):903-12. PubMed ID: 27344197
[TBL] [Abstract][Full Text] [Related]
30. Introduction of emerging medical devices on the market: a new procedure in Belgium.
Vinck I; Neyt M; Thiry N; Louagie M; Ramaekers D
Int J Technol Assess Health Care; 2007; 23(4):449-54. PubMed ID: 17937833
[TBL] [Abstract][Full Text] [Related]
31. Accessing the medical devices market in Egypt and Saudi Arabia: a systematic review of policies and regulations.
Gad M; Kriza C; Fidler A; Kolominsky-Rabas P
Expert Rev Med Devices; 2016 Jul; 13(7):683-96. PubMed ID: 27268662
[TBL] [Abstract][Full Text] [Related]
32. Introduction of high-risk medical devices: national measures that can be taken under the current European legislation to put the patient interest central.
Neyt M; Baeyens H; Pouppez C; Slegers P; Hulstaert F; Stordeur S; Vinck I
Expert Rev Med Devices; 2017 Mar; 14(3):181-188. PubMed ID: 28128008
[TBL] [Abstract][Full Text] [Related]
33. Diffusion and Use of Tethered Personal Health Records in Primary Care.
Vydra TP; Cuaresma E; Kretovics M; Bose-Brill S
Perspect Health Inf Manag; 2015; 12(Spring):1c. PubMed ID: 26755897
[TBL] [Abstract][Full Text] [Related]
34. Reform of prescription drug reimbursement and pricing in the German social health insurance market: a comparison of three scenarios.
Gress S; Niebuhr D; May U; Wasem J
Pharmacoeconomics; 2007; 25(6):443-54. PubMed ID: 17523750
[TBL] [Abstract][Full Text] [Related]
35. Testing a new taxonomic model for the assessment of medical devices: Is it plausible and applicable? Insights from HTA reports and interviews with HTA institutions in Europe.
Fuchs S; Olberg B; Perleth M; Busse R; Panteli D
Health Policy; 2019 Feb; 123(2):173-181. PubMed ID: 29703653
[TBL] [Abstract][Full Text] [Related]
36. Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.
Kandolf Sekulovic L; Guo J; Agarwala S; Hauschild A; McArthur G; Cinat G; Wainstein A; Caglevic C; Lorigan P; Gogas H; Alvarez M; Duncombe R; Lebbe C; Peris K; Rutkowski P; Stratigos A; Forsea AM; De La Cruz Merino L; Kukushkina M; Dummer R; Hoeller C; Gorry C; Bastholt L; Herceg D; Neyns B; Vieira R; Arenberger P; Bylaite-Bucinskiene M; Babovic N; Banjin M; Putnik K; Todorovic V; Kirov K; Ocvirk J; Zhukavets A; Ymeri A; Stojkovski I; Garbe C
Eur J Cancer; 2018 Nov; 104():201-209. PubMed ID: 30388700
[TBL] [Abstract][Full Text] [Related]
37. Analysis of the renewed European Medical Device Regulations in the frame of the non - EU regulatory landscape during the COVID facilitated change.
Kanti SPY; Csóka I; Adalbert L; Jójárt-Laczkovich O
J Pharm Sci; 2022 Oct; 111(10):2674-2686. PubMed ID: 35872025
[TBL] [Abstract][Full Text] [Related]
38. Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization Methods.
Leyens L; Brand A
Public Health Genomics; 2016; 19(3):187-91. PubMed ID: 27238553
[TBL] [Abstract][Full Text] [Related]
39. Health technology assessment of medical devices: a survey of non-European union agencies.
Ciani O; Wilcher B; Blankart CR; Hatz M; Rupel VP; Erker RS; Varabyova Y; Taylor RS
Int J Technol Assess Health Care; 2015 Jan; 31(3):154-65. PubMed ID: 26044729
[TBL] [Abstract][Full Text] [Related]
40. Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria.
Vassileva M; Kamusheva M; Manova M; Savova A; Tachkov K; Petrova G
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):733-742. PubMed ID: 30900482
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
